Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences >

StocksDiva Bio Bin

RSS Feed
      Hide Sticky   Hide Intro
Moderator: StocksDiva Assistants:
Search This Board:
Last Post: 10/30/2014 1:41:17 PM - Followers: 132 - Board type: Free - Posts Today: 0



 

CONSIDER THE FOLLOWING WHEN CHOOSING WHICH BIOTECH STOCKS TO INVEST IN
 
 
TOP THERAPEUTIC CATEGORY
 
Be on the look out for companies developing drugs or biologics in research areas as cardiovascular disease, diseases of the central nervous system, autoimmune diseases, cancer, AIDS, diabetes, immunological diseases, infectious diseases, respiratory diseases, and so on where there is a high degree of  incidence in the population. Success in these areas will ensure the company a faster return on their investment in R&D and licensing efforts. You should also look out for drugs with orphan drug designation, which if approved gets seven years of marketing exclusivity.
 
COLLABORATIVE SUPPORT
 
 Biotechnology companies have become the major drivers of research in collaboration with pharmaceutical companies. A strong network of collaborative support is a strong indication that a company is financially and logically stable. Pharmaceutical companies can partner with a small biotech company and provide up-front dollars, followed by further investments as scientific milestones are achieved (e.g a regulatory submission, a successful completion of a key phase 2 study or an approval of a product). The small company usually gives up one of their lead products to the partner  or has a co-marketing agreement. 
 
Apart from full incorporation of one company into another, alliances between separate companies are a necessity for successful R&D (Research and Development). One company cannot have all the expertise and resources to cover all the basic science areas germaine to  their therapeutic areas of interest. Such that one company will have access to a particular added technology or product, which is shared through alliances and licensing deals. In 2003, over 800 such collaborations were signed for the pharma to biotech and the biotech to biotech agreements.
 
SOURCES OF FUNDS
 
The financing of the industry involves a variety of sources of money needed to pay for the expensive and lengthy R&D , wherein the promise of a return (a new product) is far down the road, 5-10 years, from the first investment. The biotech segment of the pharmaceutical industry includes more than 4000 small companies worldwide with about 1500 of them in the USA and needs to employ a full range of financing to maintain their viability. It is estimated that usually 25% or more of biotech companies only have 2 years of financial capital left before they replenish their capital or go out of business. SO INVESTIGATE NEW COMPANIES CAREFULLY. It is important to consider where these companies get their funding and it can come from one of the sources listed:
  •  Partners- As mentioned above, big pharmaceutical companies can partner with a small biotech company and provide funding and further investment as scientific milestones are met.
  •  Debt-  A company can certainly go to banks and investment companies, creating debt by offering corporate bonds or taking on a loan of money, both of which pay interest to the lender, a bank or investor. The lender expects near term good news in product advancement and approval as their collateral for the loan.
  • PIPE (Private Investment in Public Equity)- this is a special funding by outside investors outside of the typical stock purchase.
  •  Venture Capital (VC)- This is often the first area of financing for a new company. The VC is a wealthy individual also known as "an angel" or a VC company. Venture Capital is provided usually in stages (up to seven) as the company advances its science and product development.
  • IPOs (initial public offering)- After a new company has progressed in their research with unique targets for disease mitigation or especially has products in a pipeline, they can go public and offer stock. Becoming a public company is a large source of income operations and it gives the company freedom to operate without the control or oversight of a partner.
  • follow-on- this is a later stock offering following an IPO. 
 
For any one company to move from a new start up company to marketing a product over the 10 years, they usually will need to employ a variety of these funding sources at different times. For publicly owned companies, you must judge whether they have excessively diluted their shares. Companies with private financing, milestone payments and sale of debt securities (secured and/or convertible) have more potential for stability than those without any of these sources.
 
ROBUST PIPELINES 
 
Make sure you look for pipelines consisting of more than one product. Several criteria are important in establishing a successful and robust pipeline. Look out for product candidates in all four stages of development, a reasonable number of product candidates in all four stages of development, a reasonable, especially given that most will ultimately fail and not be carried forward, and  a reasonable number of candidates across important therapeutic areas such as cancer.
 
POTENTIAL FOR REBOUND
 
Companies that are highly valued but has gone through some tough times might be found at a lower price. The stock market is rough on companies that have hit a temporary bad news e.g a CRL, causing the price to over react. Prices might drop temporarily as a result of a slightly bad news, for example if the FDA gives a CRL due to a labeling issue that can easily be fixed in a few months. On the other hand, Prices could also drop permanently for a long time for example FDA gives a CRL requesting that additional clinical studies be conducted to show safety or efficacy. Small biotech companies also react to any slight good news as well, from new patent approval, to FDA "accept to file" decision on a marketing application and so on.
 
MANAGEMENT 
 
 A biotech company should be run by very knowledgeable entrepreneurs, and companies whose managers have a scientific background  or a strong research experience. These CEOs, COOs, CFOs, CSO,CMOs are all very much involved in the development of the company's products. 
 
NDA-REVIEW PRODUCTS

    Look for products that are at the end of the FDA approval process, the bulk of testing has been completed on these products and the only thing the sponsor is waiting for is an approval decision to allow marketing of the product. Although by this stage, success is still not guaranteed because the FDA can deny approval for any reason even if the clinical results are perfect; They may sometimes have questions on manufacturing, labeling, and so on which could delay approval of the product.  

 

Motorbike Clip Art     Motorbike Clip Art

 

Example of a Time line on FDA approval stocks

Remember to always watch fda's and bio tech stocks very close, Keep track of the RSI...when it starts dropping...sell sell sell

    Time lines on FDA approval stocks generally has a very slim window of opportunity for making you profits.  I have gathered a time breakdown of data to show you how quickly they come into play and without delay go downward just as fast.  This particular stock opened the day at 9:30 am ET at .70 with only 300 in volume. She sat idle all trading day and as illustrated when the news hit at 2:59 pm ET, she took off like a house on fire.

 

    By 3:06 pm ET, word got around that she was approved and by 3:08 pm ET she peaked and by 3:09 pm ET, she started her downward slope.  Generally once BioTech stock with FDA approval starts her descent, you don't want to contemplate of whether to hold her, GET GREEN  and GET GONE!  Lesson learned or you might be waiting a long time for a companies pipeline to come around again. 


TIME and Sales to the end:

4:00 PM    1.07     220,854 3:31 PM    1.04     170,480 3:12 PM    1.30     137,912
3:59 PM    1.07     215,854 3:29 PM    1.00     170,362 3:11 PM    1.30     137,412
3:56 PM    1.07     214,854 3:24 PM    1.02     165,362 3:09 PM    1.425   135,712
3:54 PM    1.07     210,854 3:21 PM    1.04     154,412  
3:51 PM    1.02     210,654 3:19 PM    1.10     148,412 3:08 PM    1.50     129,022
3:49 PM    1.02     204,980 3:17 PM    1.02     143,292 3:07 PM    1.32     122,772
3:46 PM    1.02     199,980 3:16 PM    1.10     140,692

Resisted

3:44 PM    1.02     187,480 3:14 PM    1.15     138,662 3:06 PM    1.25     120,372
3:42 PM    1.03     182,980 3:13 PM    1.25     138,412 3:04 PM    1.00     114,872
3:41 PM    1.03     181,480

Started back down

3:03 PM    1.08     97,572
3:40 PM    1.03     179,980   3:02 PM    1.01     591,522
3:35 PM    0.99     178,980   3:01 PM    0.74     54,060
3:32 PM    0.88     176,480   3:00 PM    0.70     29,526

 

NEWS that made it run fast & furious Ophthalmic Imaging Systems Receives FDA Clearance to Market Revolutionary New Portable Digital Imaging Device

November 30, 2009:



02:59 PM ET (THIS IS WHERE THE APPROVAL NEWS STARTED)


9:30 AM    0.70          300 (BEGINING OF TRADE DAY)

     

 

 

FDA Drug Approval Reports

 

How FDA works Power Point Presentation

 

 

~Always do you own DD~.  Good Luck and please add this board as your favorite

StocksDiva is not paid or compensated to report news and developments about publicly traded companies

 


 


 




 
Love them as much as they Love us....They are Coming HOME!!!










Thanks for the memories and the support...You all know who I am talking about:)


PostSubject
#11218  Sticky Note SPOM -SPO MEDICAL SYSTEMS due diligence StocksDiva 02/19/13 10:45:00 AM
#10996  Sticky Note BIO EARNINGS & CONFERENCES JAN-FEB/2013 StocksDiva 12/26/12 09:59:52 AM
#10991  Sticky Note FDA Calendar 12/26/12-03/17/13 StocksDiva 12/26/12 09:01:01 AM
#10088  Sticky Note FCSC/OTCBB. DD sheet. 2 impact-videos at the end. PoemStone 11/10/12 10:32:10 AM
#11509   IMLFF used to have 500 likes on Facebook PharmaGreen007 10/30/14 01:41:17 PM
#11508   Looks great Le2dynasty. PharmaGreen007 10/29/14 03:52:21 PM
#11507   $DSCR: 5th Video - Update August 25, 2014: Le2dynasty 10/28/14 02:39:33 PM
#11506   $$$ PMBS BREAKOUT VOLUME $$$ OUTLOOK 10/19/14 03:42:13 AM
#11505   ~:*¨¨*:•.MAYBE EBOLA CURE.•:*¨¨*:~ http://news.yahoo.com/ebola-cas Lask 10/17/14 05:03:07 PM
#11504   $UNQT: Union Equity Inc. Announces Shareholder Update Le2dynasty 10/17/14 09:31:10 AM
#11503   $IDGC & $DSCR: Hemp For Victory [Full Official Le2dynasty 10/10/14 10:52:05 AM
#11502   $DSCR: 5th Video - Update August 25, 2014: Le2dynasty 10/06/14 10:17:51 AM
#11501   $RCPI bottom watch. Very oversold here. Penny Roger$ 09/17/14 09:30:27 PM
#11500   $DSCR: Hemp Process Le2dynasty 09/03/14 09:38:13 AM
#11499   $IDGC: ID Global Corporation Provides an Investment Portfolio Update Le2dynasty 09/03/14 09:26:52 AM
#11498   $DSCR: Discovery Provides Update on Hemp Seed, Files Le2dynasty 09/03/14 09:26:30 AM
#11497   $DSCR: Discovery Joint Ventures Hemp Seed Arrives Le2dynasty 09/03/14 09:26:18 AM
#11496   46 Reason Why CANLF Will Succeed, great article. PharmaGreen007 07/25/14 11:50:18 AM
#11495   CANLF, a very Unique Biotech opportunity. Here's several PharmaGreen007 07/22/14 11:12:17 AM
#11494   CTIX DD-Catalysts-Brilicidin-Anitbiotic Wonderdrug? alexwv 06/28/14 01:22:56 PM
#11493   Biotech Implications for Quantum Dots..Emerging Nanotechnology. Solar_Express 06/25/14 12:58:55 AM
#11492   GSK and THRX Announce Positive Data From Two StocksDiva 06/11/14 09:21:44 AM
#11491   PTLA Portola Pharmaceuticals Announces Positive Phase 2 Data StocksDiva 06/11/14 09:20:37 AM
#11490   NWBO DCVAX-DIRECT TRIAL UPDATE INDICATES FURTHER POSITIVE RESPONSES; StocksDiva 06/11/14 09:19:58 AM
#11489   ATNM Panelists at NewYorkBIO-CONference Highlight Prior Clinical Data StocksDiva 06/11/14 09:18:00 AM
#11488   WeedStock Conference June 29 through July 1 at StocksDiva 06/09/14 09:18:57 AM
#11487   AGIO Agios Pharmaceuticals Initiates Multiple Ascending Dose Trial StocksDiva 06/09/14 09:09:41 AM
#11486   ADXS Advaxis Announces Business Update Conference Call FOR StocksDiva 06/09/14 09:08:37 AM
#11485   ALNY Alnylam Presents New Pre-Clinical Data with Development StocksDiva 06/09/14 09:07:17 AM
#11484   GLMD Galmed Pharmaceuticals Announces the Filing of a StocksDiva 06/09/14 09:06:09 AM
#11483   Merck (MRK) surprised many folks Monday morning by StocksDiva 06/09/14 09:02:00 AM
#11482   IMMU Immunomedics Announces Orphan Drug Designation for IMMU-132 StocksDiva 06/09/14 09:00:30 AM
#11481   CBST Cubist Announces Publication of Pivotal Data from StocksDiva 06/06/14 09:10:41 AM
#11480   TTHI Transition Therapeutics Enters Into a Private Placement StocksDiva 06/06/14 09:09:23 AM
#11479   ADXS Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly StocksDiva 06/06/14 08:59:23 AM
#11478   BCLI First Patient Enrolled in BrainStorm's Phase II StocksDiva 06/06/14 08:55:19 AM
#11477   IBIO iBio European Patent on iBioModulator Technology Emerges StocksDiva 06/05/14 08:55:52 AM
#11476   CRIS Curis Announces Re-Initiation of Patient Dosing in StocksDiva 06/05/14 08:53:53 AM
#11475   MRNA Marina Biotech Receives Decision to Grant Japanese StocksDiva 06/05/14 08:52:48 AM
#11474   MDGN Medgenics Announces First Patient Implanted in Phase StocksDiva 06/05/14 08:49:57 AM
#11473   BHRT Bioheart to Present at the PRP and StocksDiva 06/04/14 09:20:10 AM
#11472   MTST MetaStat, Inc. Announces Publication of Results of StocksDiva 06/04/14 09:17:14 AM
#11471   ADXS Data Published by Researchers at the National StocksDiva 06/04/14 09:14:03 AM
#11470   AVXL Anavex Awarded New U.S. Patent http://finance.yahoo.com/news/anavex-awarded StocksDiva 06/04/14 09:12:35 AM
#11469   ARGS Treatment With AGS-003 and Sunitinib Associated With StocksDiva 06/02/14 09:16:14 AM
#11468   AQXP Aquinox Pharmaceuticals Announces Expansion of Ongoing Phase StocksDiva 06/02/14 09:13:36 AM
#11467   BIOC Biocept Expands Breast Cancer Offering http://finance.yahoo.com/news/biocep StocksDiva 06/02/14 09:10:13 AM
#11466   ARIA ARIAD Announces Longer-Term Safety and Efficacy Data StocksDiva 06/02/14 09:06:40 AM
#11465   PLPL Plandai Biotechnology, Inc. Awarded $1.3 Million Grant StocksDiva 06/02/14 09:05:13 AM
#11464   IMMU Immunomedics Reports IMMU-130 is Active in Patients StocksDiva 06/02/14 09:02:56 AM
#11463   LPTN Lpath to Present Trial-in-Progress Poster at ASCO StocksDiva 06/02/14 09:01:37 AM
#11462   BCLI Positive Interim Phase IIa ALS Data With StocksDiva 06/02/14 08:59:46 AM
#11461   BTX BioTime's Subsidiary Asterias Biotherapeutics, Inc. Announces a StocksDiva 05/30/14 09:24:09 AM
#11460   :( DARA BioSciences, Inc. Announces Pricing of $12.5 StocksDiva 05/30/14 09:22:46 AM
PostSubject